Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Zealand Living Cell-Otsuka Partnership Implants Pig Cells Into Parkinson’s Patient: AusBiotech

This article was originally published in PharmAsia News

Executive Summary

New Zealand’s Living Cell Technologies has taken a key clinical step in regenerative and replacement branded cell therapy work focused on Parkinson’s disease and type 1 diabetes that has drawn investment from Japan’s Otsuka. The progress report was presented at the Australia Biotech Invest conference in Melbourne in late October.

You may also be interested in...



New Zealand's Living Cell Technologies Closer To Getting Pigs To Market

PERTH, Australia - Auckland-based cell implant company Living Cell Technologies has started working on an animal-derived therapeutics project with the New Zealand government's investment promotion agency, Investment New Zealand

Considering Growth Options For Asian Biotechs: IPO Vs M&A

Going public via an IPO or being acquired are two ways that Asian biotech companies can grow their business, and some of the issues involved in both approaches come under discussion at a panel session at a recent conference in Singapore.

Nanjing BioPoint Shoots For 2018 Double POC Launch; Seeks $10m

A China-based IVD company, spun out of an Australian medical research institute, is seeking investors to support its plans for the 2018 launch its first two point-of-care tests for patients with infectious diseases including HIV and viral hepatitis.

Topics

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel